Price Reductions for Second Main Cycle
Summary of 1 April 2013 Price Reductions for second Main Cycle by Drug / Manner of Administration / Weighted Average Percentage Reduction
|
Drug |
MOA |
Weighted Average Percentage Reduction |
|---|---|---|
|
Aciclovir |
Oral |
37.67% |
|
Alendronic Acid |
Oral |
31.84% |
|
Allopurinol |
Oral |
18.04% |
|
Alprazolam |
Oral |
12.78% |
|
Aluminium Hydroxide with Magnesium Hydroxide |
Oral |
13.60% |
|
Amlodipine |
Oral |
40.06% |
|
Amoxycillin with Clavulanic Acid |
Oral |
19.08% |
|
Atenolol |
Oral |
19.60% |
|
Azathioprine |
Oral |
10.84% |
|
Baclofen |
Oral |
10.62% |
|
Cefotaxime |
Injection |
18.19% |
|
Cephazolin |
Injection |
55.97% |
|
Cimetidine |
Oral |
14.26% |
|
Clozapine |
Oral |
10.81% |
|
Cyproterone |
Oral |
15.92% |
|
Desferrioxamine |
Injection |
13.01% |
|
Diclofenac |
Oral |
20.62% |
|
Doxycycline |
Oral |
21.76% |
|
Fentanyl |
Transdermal |
20.88% |
|
Flucloxacillin |
Injection |
22.12% |
|
Fluconazole |
Injection |
23.30% |
|
Fludarabine |
Injection |
62.40% |
|
Fluorouracil |
Injection |
21.52% |
|
Fluvoxamine |
Oral |
13.39% |
|
Folinic acid |
Injection |
61.58% |
|
Gabapentin |
Oral |
20.50% |
|
Galantamine |
Oral |
10.12% |
|
Glimepiride |
Oral |
12.60% |
|
Granisetron |
Injection |
60.32% |
|
Granisetron |
Oral |
44.46% |
|
Hydrocortisone |
Oral |
37.70% |
|
Hydroxocobalamin |
Injection |
17.52% |
|
Ipratropium |
Inhalation |
17.02% |
|
Iron Polymaltose Complex |
Injection |
27.69% |
|
Isosorbide Mononitrate |
Oral |
10.60% |
|
Isotretinoin |
Oral |
14.80% |
|
Lactulose |
Oral |
15.63% |
|
Leflunomide |
Oral |
15.71% |
|
Lercanidipine |
Oral |
29.67% |
|
Methotrexate |
Injection |
21.14% |
|
Metoprolol |
Oral |
10.86% |
|
Metronidazole |
Injection |
44.50% |
|
Mirtazapine |
Oral |
25.18% |
|
Moclobemide |
Oral |
13.46% |
|
Norfloxacin |
Oral |
16.48% |
|
Omeprazole and Clarithromycin and Amoxycillin |
Oral |
12.07% |
|
Paclitaxel |
Injection |
86.94% |
|
Pamidronic Acid |
Injection |
50.00% |
|
Pantoprazole |
Oral |
36.82% |
|
Perindopril |
Oral |
15.78% |
|
Pindolol |
Oral |
33.64% |
|
Ranitidine |
Oral |
26.57% |
|
Salbutamol |
Inhalation |
13.73% |
|
Sotalol |
Oral |
14.55% |
|
Sucralfate |
Oral |
20.33% |
|
Sumatriptan |
Oral |
16.08% |
|
Tamoxifen |
Oral |
32.77% |
|
Terbinafine |
Oral |
25.76% |
|
Tramadol |
Oral |
19.50% |
|
Trandolapril |
Oral |
10.22% |
|
Vancomycin |
Injection |
49.90% |
|
Vinorelbine |
Injection |
21.52% |
For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI).
Notes: Following a Federal Court order on 6 December 2012 concerning two drugs in the interim supplementary disclosure cycle, changes will be required to the price disclosure process.
A drug/manner of administration in the second main cycle that has no brands in Schedule 1 or 2 of the December 2012 determination mentioned above does not have price reductions scheduled for 1 April 2013. Outstanding second main cycle reductions will not occur until after 1 April 2013. However, flow-on reductions for single brand combination items and new brands of existing items in the December 2012 determination will occur in April. Reductions may also be determined for 1 April 2013 for new brands of new pharmaceutical items with a drug/manner of administration that is in Schedule 1 of the December 2012 determination.
Following consideration of the written reasons received on 18 December 2012 for the court decision, further notice will be provided regarding the second main cycle and future price disclosure processes.
Below is a list of the Second Main Cycle drugs not in the December 2012 determination.
| Drug | MoA |
|---|---|
|
Amoxycillin |
Oral |
|
Betamethasone |
Application |
|
Bisacodyl |
Oral |
|
Calcitriol |
Oral |
|
Captopril |
Oral |
|
Carboplatin |
Injection |
|
Carvedilol |
Oral |
|
Cefaclor |
Oral |
|
Cefepime |
Injection |
|
Ceftriaxone |
Injection |
|
Cephalexin |
Oral |
|
Ciprofloxacin |
Oral |
|
Cisplatin |
Injection |
|
Citalopram |
Oral |
|
Clarithromycin |
Oral |
|
Clopidogrel |
Oral |
|
Codeine with Paracetamol |
Oral |
|
Cyclosporin |
Oral |
|
Dicloxacillin |
Oral |
|
Diltiazem |
Oral |
|
Dothiepin |
Oral |
|
Enalapril |
Oral |
|
Epirubicin |
Injection / intravesical |
|
Etoposide |
Injection |
|
Famotidine |
Oral |
|
Fluconazole |
Oral |
|
Fluoxetine |
Oral |
|
Fosinopril |
Oral |
|
Gemcitabine |
Injection |
|
Gemfibrozil |
Oral |
|
Gentamicin |
Injection |
|
Gliclazide |
Oral |
|
Irinotecan |
Injection |
|
Lamotrigine |
Oral |
|
Lisinopril |
Oral |
|
Medroxyprogesterone |
Oral |
|
Metformin |
Oral |
|
Norethisterone with Ethinyloestradiol |
Oral |
|
Oestradiol |
Transdermal |
|
Omeprazole |
Oral |
|
Paracetamol |
Oral |
|
Paroxetine |
Oral |
|
Pravastatin |
Oral |
|
Quinapril |
Oral |
|
Ramipril |
Oral |
|
Risedronic Acid and Calcium |
Oral |
|
Risperidone |
Oral |
|
Roxithromycin |
Oral |
|
Sertraline |
Oral |
|
Simvastatin |
Oral |
|
Timolol |
Application to the eye |
|
Topiramate |
Oral |
|
Verapamil |
Oral |
|
Vincristine |
Injection |
